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Mycobacterium avium subsp. paratuberculosis (MAP) causes Johne’s disease 
(JD) in ruminants.  Development of genetic tools and completion of the MAP genome 
sequencing project expanded opportunities for antigen discovery. In this thesis, I review 
the current trends in diagnosis and disease control of JD and present the results of the 
studies on the seroreactivity of two proteins encoded for by the MAP1152-MAP1156 
gene cluster.  MAP1152 encodes for a PPE protein and MAP1156 encodes a 
diacylglycerol acyltransferase involved in triglyceride metabolism and classified in the 
uncharacterized protein family UPF0089. Maltose-binding protein (MBP) tagged 
recombinant MAP proteins were purified from Escherichia coli. Western immunoblotting 
analysis indicated that both MAP1152 and MAP1156 displayed reactivity against sera of 
immunized mice and rabbits, and naturally infected cattle.  MAP1156 yielded a stronger 
positive signal than MAP1152 against sera from cattle with JD. An enzyme linked 
immunosorbent assay (ELISA) for the recombinant proteins was developed and used to 
test pre-classified positive and negative serum samples from naturally infected and non-
infected cattle. Samples, with one exception, displayed no seroreactivity against MBP-
 
 
LacZ (P > 0.05), the negative control antigen. MAP1152 displayed seroreactivity against 
all positive sera, but no seroreactivity to the negative sera (P < 0.01). MAP1156 
displayed stronger and more variable reactivity than MAP1152, but significant 
differences were observed between non- infected and infected cattle (P < 0.05). 
Otherwise, degrees of reactivity followed the same trend as the positive reference 
antigen. In conclusion, MAP infected cattle mount a humoral response to both MAP1152 
and MAP1156. These findings have potential applications to diagnostics, vaccine 
production, and elucidation of the immuno-pathogenesis of JD.
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CHAPTER 1 
LITERATURE REVIEW 
 
Introduction 
Johne’s disease (JD) is caused by Mycobacterium avium subspecies paratuberculosis 
(MAP) (40, 68).  JD is an incurable, chronic, contagious, malabsorptive diarrheal 
condition of cattle, sheep, other ruminants, and some wildlife (25, 40, 68).  The diarrhea 
leads to malnutrition, progressive weight loss, debilitation, and eventually death.  Thus, 
producers suffer economic loss through premature culling of clinical or sub-clinical 
animals (73).  Dairy producers suffer additional loss from repeated testing to determine 
infectious status of their herds, culling false positive test animals, lost milk production, 
and lost cow longevity due to MAP infection.  The annual economic impact to the diary 
industry is estimated at $276 per cow per lactation for infected cows on a dairy (131). 
While less well studied and characterized for beef cattle producers, JD still causes loss to 
the industry. Beef cattle producers suffer economic loss from lower cow fertility and 
longer time open during breeding and gestation periods, lost weight and weight 
maintenance, lower calf birth-weight, and lower calf weaning weight due to infection (53, 
54). The annual economic impact to the beef industry is more difficult to estimate than in 
the dairy industry. However, producers report added value if their herds are deemed 
disease free (54, 79). Managing a herd to treat or prevent JD is difficult due to the hidden 
transmission by subclinically infected cattle that often appear healthy (153).  Sub-clinical 
animals are difficult to detect because of the in-accuracy of diagnostic techniques for 
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testing individual animals (15, 43, 157, 160, 180).  The inaccuracy that affects sensitivity 
of diagnostic tests for JD lies in the inability to detect the infection until the animal is 
well into the infectious cycle.  The inaccuracy affecting specificity of JD diagnostic test 
lies cross reactive indicators of the disease.  These inaccuracies are discussed further as I 
break down the diagnostic techniques available to veterinarians and producers.  
Vaccination is not recommended for several reasons including the potential to render 
animals crossreactive with the Mycobacterium bovis (Bovine tuberculosis) skin test, and 
the lack of efficacy of currently available vaccines (14, 24, 75, 149, 167).  Understanding 
the transmission of JD and developing a herd testing strategy can help producers maintain 
herd biosecurity and biocontainment (43, 65-67).  Here we review transmission trends in 
Johne’s disease, diagnostic testing strategies, measures producers can take to avoid or 
reduce Johne’s disease within their herds, and describe MAP pathogenesis and genetics 
as they relate to diagnostic test development and strategy.  
Transmission of Johne’s Disease 
The first factor to understand in the transmission of JD is that cattle less than a year of 
age are the most susceptible to MAP.  A recent review (179) analyzed the age 
susceptibility of cattle to MAP exposure.  Calves less than 6 months of age are the most 
susceptible, 75% progress to clinical disease after exposure.  Calves 6-12 months have a 
lower rate of infection and progression to clinical disease (50%).  Cattle older than 12 
months are the least susceptible; less than 20% progress to clinical signs of disease.  The 
percentage of infection was also found dose dependant in this study.  Thus, the authors 
suggest commingling calves with high shedding animals can expose calves of the age 
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groups to equivalent amounts of MAP infectious dose as used in the study, thereby 
lending weight to their findings of progression to infectious disease. 
Calves are the most susceptible population for several possible reasons, though there 
is incomplete understanding of susceptibility trends.  Reasons include heightened 
exposure to manure through nursing during the first months of development, differences 
in gut physiology between adult cattle and calves, MAP exposure transmitted through the 
milk of the dam, the calf reliance on passive immunity during the first months of 
development, and possible in-utero infection before parturition (179).  Consideration of 
these factors guided consensus recommendations for maintaining hygienic neo-natal calf 
practices by limiting exposure to MAP (6, 67, 83, 95, 154, 162).  
Exposure to manure through nursing, contaminated feed, and contaminated water 
supplies are the most common sources of exposure (148, 177).  Also demonstrated is the 
isolation of MAP from aerosolized particles of dust and dry manure in barnyard 
environments (48).  The threat of aerosolized MAP particles is not well characterized, but 
it does present an exposure/transmission route by inhalation or ingestion depending on 
the shed bacterial load within the herd.   
Due to these exposure routes, it is recommended that calves be removed from their 
dams as soon as possible; within the first 24 hours of life.  Feeding replacement 
colostrum, if possible, also may reduce the risk of MAP exposure (114, 154).  However, 
feeding pooled colostrum and pooled milk should be avoided, or the fed colostrum and 
milk should be pasteurized to reduce the risk of MAP exposure (114, 142, 154).  Calves 
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should not receive feed with possible manure contamination.  Loaders and wagons used 
for hauling manure should not be used for transporting feed.  Feed bunks and creep 
feeders should be cleaned daily.  Water sources for calves should be separate from that of 
older cattle and should be checked to assure contamination is not possible due to run-off 
from feedlots and milking barns. 
In-utero (178), blood to blood (119), respiratory secretions (35), and transmission 
through semen (7) can also occur, though are less common routes of 
exposure/transmission, and only occur when the adult cattle are in advanced stages of the 
disease.  However, these possible routes hinder eliminating JD from a herd, and should 
be taken into account with measures to limit exposure of calves post-parturition.  Thus, 
culling of any animal showing clinical signs and off-spring from that animal is highly 
recommended to limit the spread of JD (43, 102, 131, 133, 134).  Culling in itself will 
reduce the amount of shed MAP in a herd and the environmental load of MAP, but it is 
not enough to eliminate the agent from a herd (102).   
Testing and herd management strategies must be employed beyond culling to limit 
the transmission of JD, because the clinical signs of JD do not develop for years.  This 
creates an iceberg effect whereby the largest population of cattle infected with MAP is 
undetectable.  Thus, within herd transmission occurs because sub-clinically infected 
cattle shed the bacteria to their young and other calves.  Between herd transmission 
occurs when healthy appearing, sub-clinically infected cattle are introduced in the herd to 
increase herd size, or purchase of replacement heifers and bulls.   
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Diagnosis 
There are several common, commercially available diagnostic tests for the detection 
of MAP infection, the use of each is dependent upon what the producer aims to 
accomplish in their control of JD and whether they are seedstock producers or 
commercial production ranchers (32).  Seedstock producers should aim at maintaining a 
disease free status of their herd, thus their testing strategy should be much more stringent.  
Tests of high specificity are indicated for seedstock producers to insure correct diagnosis.  
Likewise, commercial production ranchers should desire to maintain disease free status, 
but may be more open in their cattle replacement and marketing strategies.  Commercial 
producers should aim at using cost effective screening tests that are sensitive, and then 
following up positive test results with a test of higher specificity to insure correct 
diagnosis.  Commercial producers should also practice purchasing from test negative 
disease free herds, and this point will be elaborated further in the next section on disease 
control.   
The most common diagnostic tests available are: culture of the bacteria from the feces 
of animals, testing for DNA/RNA of the bacteria (Polymerase Chain Reaction, PCR; or 
Real Time Polymerase Chain Reaction, RT-PCR), serological tests (Enzyme Linked 
ImmunoSorbent Assay (ELISA)), and tests for cellular immunity.  Each of these tests has 
its benefits and drawbacks, and there is a large investment in research aimed at improving 
the performance of each. 
Culturing the bacteria from feces is very specific (estimated at 99.9%), because MAP 
is isolated and visually apparent, and readily accessible for IS900 PCR confirmation and 
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typing (175).  However, bacteria must be shed in relatively high numbers, making this 
test low in sensitivity (estimated at 35 – 40%) in the detection of sub-clinical animals and 
animals in the initial stages of the disease (37, 44, 45, 173).  MAP takes 2 months to grow 
on culture medium.  The culture technique is prone to contamination and cultures can 
result in false positive identifications, reducing specificity (37, 89, 110), as illustrated by 
the concept of passive shedding (R. Whitlock, Pennsylvania State University, personal 
communication at the 10
th
 International Colloquium on Paratuberculosis).  Whitlock et. 
al. have demonstrated that in herds that contain animals classified as “super shedders”, 
the environmental bacterial load can be high enough for adult cattle to graze and shed the 
bacteria without becoming truly infected.  The absence of infection in these passive 
shedding cattle was confirmed by serology, and histology after necropsy.  However, their 
data do not conclusively show how long a passive shedder can harbor MAP and shed it in 
high enough numbers to be cultured.  Culture is also labor intensive, making it 
impractical for testing large numbers of cattle.  Even with these limitations, culture 
remains the gold standard to which other diagnostic tests are compared (20, 23, 33, 47, 
81, 85, 92, 107, 140, 150, 157, 168).  It has been employed in environmental testing 
strategies (4, 18, 101, 124, 132).  Culture of MAP from milk has been used as a herd 
testing strategy and for protection of the milk supply (8, 49, 64, 157).  Culture of pooled 
samples has also been employed for herd level diagnosis and management (45, 87, 90, 
164, 169, 172).  Culture of environmental samples, milk, or pooled fecal samples can tell 
a producer if MAP is present within their herd.  However, individual animal 
identification cannot be achieved by these methods.  Thus, it is not recommended that 
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seed stock producers take these approaches without proper additional individual animal 
testing. 
MAP DNA testing (Real Time-PCR) has become more common (21, 28, 30, 36, 50-
52, 81, 116, 123, 143, 171).  This test uses MAP DNA isolated based on established 
procedures (144) from either fecal material or milk.  Attaining enough DNA can be 
problematic, though the detection limits are becoming better with more advanced 
methods.  While molecular testing is faster than culture (results coming back within days) 
(55), it is also expensive and requires experienced personnel (21, 55, 117).  However, 
advances have been made in using both culture and Real Time - PCR for environmental 
sampling (4, 34, 176). 
Serological testing  is widely used for herd surveillance (23, 31, 33, 39, 70, 74, 76, 
77, 83, 95, 102, 108, 109, 134, 157, 163, 164, 173, 175).  Serological testing is rapid 
(results coming back within days) and relatively in-expensive, making it possible to test 
large numbers of animals.  However, cross-reactive antibodies can elicit false positive 
test results and reduce specificity of this approach (1, 10, 115, 120, 125).  A negative test 
result is also inconclusive as the animals may have not yet seroconverted or produced 
sufficient antibodies for detection in  ELISA tests (173, 175). 
Testing for the Cell Mediated Immune (CMI) inflammatory responses requires the 
animal be injected with MAP Purified Protein Derivative (Johnin PPD) (60, 86, 156).  A 
minimum of 48 hours later, the skin test is read.  In another linked test of the cellular 
immune response, blood is drawn and a test is performed for the presence of interferon 
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gamma, an inflammatory cytokine secreted by immune cells upon stimulation of the 
immune cells by the Johnin PPD.  Alternatively, detection of IL-10 in response to 
Mycobacterium antigens, specifically the MAP41 PPE protein, has been shown as an 
additional CMI indicator of disease (111). Detection of CMI is speculated to be more 
accurate than the other methods for detecting early infection (17, 78, 86). However, other 
infections induce interferon gamma production and cattle need to be in a healthy state 
when tested, or the specificity is reduced (3, 22, 156). The test is also labor intensive 
(running the cattle into a head chute twice to inject the PPD and then 48 hours later 
reading the test and drawing blood) and expensive.  Finally, the Johnin PPD can cause 
serious reaction in personnel in the event of accidental injection. 
Recommendations on using these tests for control programs were summarized by 
Collins et. al. and were accepted by the National Johne's Working Group and JD 
Committee of the US Animal Health Association during their annual meetings in October 
2006 (32).  Rather than initially testing individual animals, an accepted strategy is 
serological analysis of a statistically representative sample of animals within a herd, with 
follow-up of positive animals with a specific test, culture being the standard.  Seedstock 
producers should take this approach, with continued year to year testing, to maintain a 
test negative herd status.  Another test strategy available to commercial producers is to 
test the cattle environment and/or bulk milk coming from the establishment.  While this 
strategy will not determine which animals are infected, it is a more cost effective 
approach as an indicator that MAP is present within the herd and the calves are at risk for 
JD.          
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Treatment 
   Treatment of JD with antibiotics is rarely practiced and used only in cattle 
showing clinical signs who have genetic value for production (68, 151-153).  MAP is 
susceptible to several kinds of antibiotics, including monensin sodium (71, 72).  Reports 
indicate treatment of MAP with antibiotics reduces pathogen shedding but does not 
eliminate disease.  Due to the inability of detecting subclinical infection, the only 
alternative is to feed antibiotics in bulk with feed; a dangerous practice that increases 
antibiotic resistance and decreases antibiotic effectiveness (2, 80, 126, 181). 
Available vaccines against JD are tightly regulated and are only administered under 
special circumstances.  If the vaccine is given, producers may lose the ability to 
distinguish if their herds have been infected with Mycobacterium bovis (94, 138) by 
traditional caudal fold tests.  The vaccine efficacy is also limited.  Studies have focused 
on the efficacy as a measure of reduction in cattle that show clinical signs of disease and 
a reduction in the amount of MAP shed by the animals within a herd (84, 88, 138).  The 
vaccine does not necessarily prevent infection and MAP is still transmitted by fecal 
shedding.  Prevention of disease transmission with-in or between herds is a better 
measure of control. 
Controlling JD: Prevent the Transmission 
  Biocontainment in the case of JD is the recognition of the infection within a herd, 
and the practice to contain and eliminate that infection.  It is aimed at preventing calves 
from being exposed to the agent from the adult cow herd.  Control measures for 
eliminating sources of contamination within herd include: 
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 • Culling clinical, shedding cattle 
• Eliminating standing water supplies 
• Cleaning barns regularly and extensively 
• Cleaning feed bunks and feeders regularly 
• Avoiding use of loaders and wagons to haul manure that will be used to transport 
feed 
• Avoiding leader-follower grazing practices with older to younger cattle 
populations 
• Preventing cattle from grazing crop land recently fertilized with liquid or dry 
manure  
• Feeding calves pasteurized colostrum if possible 
• Avoiding the feeding of pooled sources of milk or colostrum as these sources 
present a greater risk for MAP exposure 
• Segregating calves from cows as soon as possible (within 24 hours) after birth 
• Segregating cows showing signs of JD from their calves and the herd 
Animals should not be used as replacement stock from a herd deemed infected with 
MAP.  In an infected herd, within herd replacement strategies seem to mask the infection 
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as older, clinical cattle are potentially replaced with sub-clinical, healthy appearing cattle.  
A better replacement strategy is to obtain cattle from a test negative herd. 
Biosecurity: Preventing Between Herd Transmission 
Biosecurity for JD should be aimed at preventing the introduction and purchase of 
infected cattle.  Dairies should avoid sending calves to calf rearing feedlots as there is a 
greater chance of exposure to MAP (135).  Pre-purchase testing is NOT effective at 
preventing the purchase of infected cattle due to the inaccuracy of the diagnostic tests 
discussed (56, 96, 128).  It is more effective to purchase replacements from test-negative 
herds even if that animal has not been individually tested.  The risk of introducing JD is 
dependent on the number of animals purchased (Figure 1), but is greatly reduced when 
purchasing from a herd that has been herd tested and classified negative.  The bottom line 
is that buying an untested animal from a tested negative herd is safer than buying a tested 
animal from an untested herd (Figure 1).  
Pathogenesis 
MAP is one of the slowest growing mycobacteria (97).  It takes 2 months for 
MAP colonies to appear on specialized medium (98).  These culture plates are kept at 
constant temperature, oxygen content, and humidity.  The incubation period within the 
host animal is approximately 3 years (174, 177, 179).  The duration of each stage of 
infection depends on age of host at the time of exposure and the dose of microorganisms 
ingested.   
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Mycobacterium species that are pathogenic illicit a chronic inflammation 
characterized by the appearance of granulomas (tubercles) due to the immune response to 
these intracellular pathogens.  The portal of entry for MAP is most often the fecal-oral 
route.  MAP targets the Mucosal Associated Lymphoid Tissues (MALT) of the ileal 
Peyers patches (103).  To attain access to MALT, MAP must traverse the intestinal 
epithelium and sub-epithelium spaces.  MAP induces endocytosis by M-cells with 
specific adherence to fibronectin binding protein (61, 62, 146, 147).  It moves through 
these M-cells in a non-lytic fashion.  Macrophages phagocytose MAP once it traverses 
the epithelium.  Multiplication and death of MAP may occur simultaneously in infected 
macrophage.  The intracellular residence results in consequential cytokine production, 
recruitment of Th1 cells, and a subsequent cell mediated inflammatory response.  
Intestinal granuloma formation occurs (141), and this inflammatory process leads to the 
clinical signs of the disease.  Detectable adaptive immunity can occur anywhere from 
several months to years after infection (121, 158).  This variability in immune responses 
adds to the difficulties of using serological tests to diagnose JD.  
After an animal ingests MAP, a strong lymphoproliferative inflammatory 
response occurs, followed by a long latent period, then a decline in cell mediated 
immunity (91, 93).  The initial lymphoproliferative response shows a marked increase in 
the expression of IL-2, IL-5, GATA-3, tissue inhibitors of matrix metalloproteinases 1 
and 2, and factors promoting apoptosis (141).  Tumor necrosis factor alpha (TNF-) is 
the dominant cytokine in the pro-inflammatory cascade (141). Chemokines, most notably 
CCL2 and CXCL10, aid in the recruitment of additional immune inflammatory cells to 
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the site of infection.  These cytokine and chemokines are produced by infected 
macrophage.  The cell signals and cytokines organize the granuloma.  A granuloma is a 
dense focus of infected macrophages, surrounded by foamy macrophages (macrophage 
undergoing expression of cytokines, chemokines, reactive oxygen species (ROSs), 
metabolites, and lipids) and non-infected monocytes (141).  Natural killer cells T-cells, 
CD4
+
, CD8
+
, and  T – cells are also present in the granuloma (141).  A fibrous network 
of collagen, fibronectin, and other extracellular matrix (ECM) components provides a 
structural framework for containment and adhesion of bacterial and immune cells.  The 
granuloma forms within capillary beds, due to continuous blood and nutritional supply.  
As the disease progresses the granuloma becomes more densely compacted with the 
ECM fibrous cuff and the number of blood vessels penetrating the structure diminishes 
markedly.  The density and compaction of the granuloma provides for a dynamic 
interaction of bacterial and immune cell response.  This interaction is characteristic of the 
containment phase of the disease (141).  While the bacteria are contained to the 
granuloma, they persist, most likely in foamy macrophages, which provide a nutrient rich 
environment for bacterial replication (40, 141).  However, in JD, damage to the intestine 
integrity is created by the density and compaction of the granuloma.  The intestinal wall 
becomes densely compacted with “scar” tissue, thickening and flattening, losing the 
ability to uptake liquids and nutrients in a normal fashion.  The thickening of areas also 
causes thinning of other areas, and the intestine in these thinner areas is more prone to 
perforation and abscess. 
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The decline in cell mediated immunity seems to occur because of disruption of 
the gene activation and signaling cascades within the macrophages infected with MAP 
(93, 141).   This can occur with a change in immune status of the host; age, malnutrition, 
or co-infection with other pathogens.  Malnutrition occurs readily in MAP infections due 
to thickening and hardening of the intestinal epithelium as the inflammatory response 
persists, as well as when MAP becomes systemic and the animal is dedicating most of its 
energy to maintaining an immune response.  There is a reduction in continued signaling 
from CD4 T cells associated with the decline in cell mediated immunity.  The cytokine 
profile shifts with an increase in IFN-, IL-4, and IL-10 (111, 112, 141).  This shift also 
creates a shift from a cell mediated immune response to humoral immune response and 
antibody production.  The granuloma decays into cellular debris, and MAP can move 
systemic through the blood stream.  The humoral response is unable to contain the 
infection and most host animals become clinical at this stage of infection. 
The effects of macro- or micro-nutrient environments to the manifestations of JD 
have been recently analyzed (104, 155).  These studies determined that altering the 
nutritional environment by appropriate trace element supplementation and liming may 
assist in controlling the clinical stage of JD.  These findings suggest a role of 
acidification, excess iron and molybdenum, and deficiencies in copper and selenium in 
the clinical manifestations of JD.  Lower calcium intake by beige mice aided resistance to 
MAP infection.  This is important in the pathogenesis of JD because supplementing cattle 
with mineral salts and calcium while improving milk production, may hinder the animal’s 
ability to maintain a cell mediated immune response and containment of MAP infection. 
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Reservoirs of JD include all domestic or wild ruminants, several non-ruminants, 
birds, and open ecological niche (5, 68, 102).  Ruminants, including cattle, sheep, and 
deer, are primary carriers. MAP has been isolated from fox, stoat, weasel, crow, rook, 
jackdaw, rat, wood mouse, hare, and badger (16).  MAP can seemingly survive in 
environments such as water sources, dust, and soil (48, 57).  Every country has cattle 
herds affected by MAP, though not every infected herd is isolated (143).  It affects an 
estimated 21–40% of cattle herds in Europe and North America.         
Genetics 
The sequencing of the MAP genome ushered in a new era of research for finding 
diagnostic and prognostic indicators, construction of live-attenuated vaccines, and 
treatment targets for controlling JD (99).  The pathogenic strain K-10 (59) was used by Li 
et. al. as the best candidate of low in vitro passages to retain virulence factors and other 
genes of pathogenic importance.  The MAP genome is 4.83 MB in size, encodes 4,344 
open reading frames (ORFs), 45 tRNAs, one rRNA operon, and has a 69.3% GC content.  
Of the ORFs, 60% have known functions, and 25% encode putative proteins of unknown 
functions.  There is a high level of redundancy within the MAP genome due to gene 
duplication, approximately 50% of genes have duplications.  Open reading frame sizes 
range from 114 bp (a ribosomal subunit encoding gene) to 19155 bp (a peptide 
synthetase).  A total of 52.5% of genes are transcribed with the same polarity as the 
origin of replication. One hundred and fifty genes are regulatory in function.  Insertion 
elements are abundant throughout the genome (20 different insertion elements with 58 
copies) and one unique element (IS900) has been used in PCR diagnosis (81, 105).  There 
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are 39 predicted proteins unique to MAP.  Important differences with other mycobacterial 
genomes include:  no intact PE-PGRS homologues, 39 PPE genes (68 in Mycobacterium 
tuberculosis (MTB)), and the presence of a truncated salicyl-AMP ligase gene (mtbA) 
which seems to underlie a MAP defect in mycobactin biosynthesis.  We pictured the 
locations of characterized virulence factors, PE and PPE genes, genes for iron utilization, 
surface polysaccharides, lipopolysaccharides, surface proteins and antigens, heat shock 
and detoxification proteins, secreted and adaptive proteins, and large sequence 
polymorphisms (Figure 2), all of which are important diagnostic and prognostic 
indicators of disease.  The sequences of known virulence factors, large sequence 
polymorphisms, and the PE, PPE proteins map together in clusters.  Differences in gene 
organization may lead to a context-dependent function, as for example, MAP gene 
homologues in other mycobacterial species may play different roles in pathogenesis.  
This hypothesis is discussed further in the context of our studies on PE and PPE proteins         
PE PPE Proteins 
Approximately 1% of the MAP genome encodes members of the PE (Pro-Glu) and 
PPE (Pro-Pro-Glu) protein families, so denominated by their characteristic motifs at their 
N-terminal domains. These genes were initially discovered in the MTB genome, which 
dedicates approximately 10% of its coding capacity to these elements. Cole et al. 
hypothesized that the PE and PPE families may have immunological importance, being 
the main source of antigenic variation (29, 159, 165). This quantitative difference in 
coding capacity seems to be rooted in the evolutionary expansion of these families as 
microorganisms of the MTB complex diverged from the M. avium group (63). MAP 
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possesses only the ancestral members of these families. Thus, functional analyses of these 
proteins are significant for the development of vaccines and diagnostics, as well as for the 
understanding of their roles in JD pathogenesis. 
Compared with MTB, PE/PPE proteins of MAP have a higher single-base 
substitution frequency, supporting the hypothesis that they are recognized by the immune 
system and are subject to positive selection (58, 99).  There are no PE-PGRS identified in 
the K-10 genome, although this subfamily has been identified and associated with PE and 
PPE proteins in other mycobacteria including M. bovis and M. marinum (13, 99).  PE-
PGRS proteins are also absent in M. avium and M. leprae (29, 99). PE and PPE proteins 
are also tempting targets for antimicrobial therapy due to their uniqueness and possible 
unique expression patterns in mycobacterial pathogenesis (99).     
PE and PPE proteins are strong humoral and cell mediated immune response antigens 
(19, 106, 111, 118, 122).  In a recent study by Nagata et. al. recombinant MAP41 was 
shown to induce IL-10 production in calves infected with MAP (111).  This is important 
in the context of their study for two reasons.  IL-10 has inhibitory effects on macrophage 
anti-microbial activity, preventing expression of MHC class II and co-stimulatory 
molecules needed on the surface of macrophages for Th1 activation.  This creates a shift 
from a cell-mediated immune response to a humoral immune response.  As discussed, 
shifting from a cell-mediated immune response to a humoral immune response in MAP 
infection is detrimental to the containment phase of the disease.  Nagata et. al. used this 
as a CMI diagnostic indicator, showing that IL-10 production upon stimulation with the  
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recombinant PPE protein MAP41 was significantly higher in animals infected with MAP 
than with other mycobacteria, or cattle never exposed to MAP.   
Another interesting hypothesis in that this and other PPE proteins may also be 
responsible for a shift from CMI to the humoral immune response.  In the next chapter, 
we show that animals infected with MAP mount humoral immune response to a different 
PPE protein, MAP1152, and a protein within the same genetic cluster, MAP1156.        
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Figure 1. Probability of purchasing one or more MAP infected animals.  The 
probability of purchasing MAP infected animals was modeled under different conditions; 
from a Johne’s infected herd (red line), from a herd of unknown untested status without 
testing the animal (blue dashed line), from a herd after testing an individual animal 
(purple line), from a tested herd (green dashed line), from a herd with continued 
monitoring (gray line). 
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Figure 2. Genomic map indicating locations of key Mycobacterium avium 
subspecies paratuberculosis ORFs.  From the outer most circle genes for characterized 
virulence factors, PE and PPE genes, genes for iron utilization, surface polysaccharides, 
lipopolysaccharides, proteins and antigens, Heat shock and detoxification proteins, 
secreted and adaptive proteins, and large sequence polymorphisms were mapped using 
NCBI Entrez and Geneious 4.6 (Biomatters Ltd.) 
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CHAPTER 2 
IMMUNOGENICITY AND REACTIVITY OF NOVEL MYCOBACTERIUM AVIUM 
SUBSPECIES PARATUBERCULOSIS PPE MAP1152 AND CONSERVED MAP1156 
PROTEINS WITH SERA FROM EXPERIMENTALLY AND NATURALLY 
INFECTED ANIMALS 
 
Copyright @ American Society for Microbiology, Clinical and Vaccine Immunology, 
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Introduction 
Information obtained from the MAP genome sequencing project ushered the 
development of new tools for diagnosis and disease control (99).  In the context of our 
study, approximately 1% of the MAP genome encodes members of the PE (Pro-Glu) and 
PPE (Pro-Pro-Glu) protein families, so denominated by their characteristic motifs at their 
N-terminal domains.  These genes were initially discovered in the Mycobacterium 
tuberculosis (MTB) genome, which dedicates approximately 10% of its coding capacity 
to these elements. Cole et al. hypothesized that the PE and PPE families may have 
immunological importance, being the main source of antigenic variation (29, 159, 165). 
This quantitative difference in coding capacity seems to be rooted in the evolutionary
                                                             
1 AP contributed the ELISA development, methods, and analysis, along with assistance on and 
confirmation of the gene maps, tables, protein analysis, and overall production of the manuscript. 
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expansion of these families as microorganisms of the MTB complex diverged from the 
M. avium group (63). MAP possesses only the ancestral members of these families. Thus, 
functional analyses of these proteins are significant for the development of vaccines and 
diagnostics, as well as for the understanding of their roles in JD pathogenesis. 
This study focused on the MAP1152-MAP1156 gene cluster as the Tn5367 
transposon insertion in a colony morphology MAP strain K-10 mutant with an attenuated 
phenotype in bovine macrophages, was now mapped ca. 0.6 kb upstream from 
MAP1152. To evaluate the potential role of this gene cluster in MAP immunobiology, we 
performed further bioinformatic analysis and determined the reactivity of MAP1152 and 
MAP1156 against sera from experimentally infected mice and rabbits, and 
experimentally and naturally infected cattle. 
 
Materials & Methods 
Cloning, expression, and purification of MAP proteins in Escherichia coli. 
MAP1152 and MAP1156 coding sequences were amplified from MAP K-10 genomic 
DNA and cloned into the pMAL-c2 translational fusion expression vector using primers 
5’- ATCCTCTAGAATGGATTTCGGGTCGTTACCGC-3’ and 5’- 
GCGCAAGCTTCTATTTCGCGTTCGGCG-GAATG-3’ for MAP1152 and 5’- 
ATCCTCTAGAATGAAACGGCTTTCGAGTGTCG-3’ and 5’- 
GCGCAAGCTTCAGCCGGTCTCGCCCGCGGCG-3’ for MAP1156.  Both primer 
pairs amplified the full-length coding sequences. The vector and amplification products 
were digested with XbaI and HindIII.  Following overnight ligation at 4°C, the products 
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were transformed into E. coli DH5α and selected on LB agar plates containing 0.10 
mg/ml ampicillin. Drug-resistant colonies were screened by and plasmid DNA for 
sequencing analysis was isolated from positive colonies to confirm each clone. E. coli 
protein lysates from verified clones were prepared as previously described (12, 137). 
Proteins used in this study were expressed and purified as N-terminal maltose-binding 
protein fusions (e.g. LacZ, MAP1152, MAP1156 for short thereafter, with the 
understanding that all recombinant proteins used in experiments are fusion products). 
These MBP-tagged recombinant proteins were overexpressed by induction of 1.0 L LB 
broth cultures with 0.3 mM isopropyl-β-D-thiogalactopyranoside (Sigma Chemical 
Company, St. Louis, MO) for 2.5 h with shaking at 37°C.  E. coli cells were harvested by 
centrifugation at 4,000 x g and resuspended in column buffer and the cell suspension was 
subjected to a freeze-thaw cycle at -20°C and sonicated using conditions described 
previously (9). The resulting crude extracts were purified by affinity chromatography 
using an amylose resin (New England Biolabs). Purified protein yields were determined 
from eluted fractions with a NanoDrop spectrophotometer set at 280 nm. The most 
concentrated fractions were pooled and dialyzed in Slide-A-Lyzer cassettes (Pierce 
Biotechnology Inc., Rockford, IL) immersed in 1.5 L phosphate-buffered saline (PBS; 
150 mM NaCl, 10 mM Na2HPO4, pH 7.4) with three exchanges at 4°C. Purified protein 
aliquots were stored at -20°C. After thawing aliquots, protein yield was re-assessed by a 
modified Lowry Assay using Bovine Serum Albumin (BSA) as the standard. E. coli 
DH5α harboring the parental plasmid pMAL-c2 was expressed, purified and used as a 
control. Purified protein from this control strain consists of an MBP fusion (overall MW, 
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42 kDa) with the LacZ alpha peptide (8 kDa). Each recombinant protein was further 
evaluated by GelCode Blue (Pierce Biotechnology Inc., Rockford, IL) stained SDS-
PAGE gels to assess purity and expected size. 
Electrophoresis and immunoblot analysis. Gel electrophoresis was performed 
using 12% (w/v) polyacrylamide gels. Electrophoretic transfer of proteins onto pure 
nitrocellulose was carried out using a Bio-Rad Trans Blot Cell (Bio-Rad Laboratories, 
Richmond, CA, USA) with sodium phosphate buffer (25 mM, pH 7.8) at 0.8 A for 90 
min. After transfer, filters were blocked with PBS plus 2% BSA and 0.1% Tween 20 
(BSA-PBST). Cattle serum samples (Table 1) were diluted 1:500 in BSA-PBST, and the 
rabbit and mouse sera were diluted 1:1,000. As necessary, subclinical (stage 2) versus 
clinical (stage 3) infection was assessed by fecal counts as described previously (175).  
For detection of MBP, a high titer murine anti-MBP monoclonal antibody was diluted 
1:10,000.  Each blot was incubated at room temperature for 2 h with gentle rocking. After 
three washes in PBS plus 0.1 % Tween 20, blots were incubated for 1.5 h in a horse 
radish peroxidase labeled goat anti-bovine detection antibody that was obtained from 
Southern Biotechnology diluted 1:10,000 in PBS-BSA. The blots were again washed 
three times as described above and developed for chemiluminesence using Supersignal 
detection reagents (Pierce). 
Quantitative analysis of band intensity on immunoblots. Band intensity was 
determined using the Adobe Photoshop CS3 extended application measurement tool. This 
version has the ability to record pixel gray values using the default measurement scale (1 
pixel = 1 pixel). Each spot was measured identically using a defined window area. Values 
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were exported into a spreadsheet for further analysis. The background statistics were 
calculated by determining the mean and standard deviations of the bands that had the 
least signal intensity within each output graph. Each intensity score was normalized to 
this calculated background intensity. 
Enzyme Linked Immunosorbant Assay (ELISA). This test was developed to 
quantify the reactivity of MAP1152 and MAP1156 proteins with a subset of serum 
samples from cattle of known exposure to MAP (Table 1). Antigen (0.010 mg per well) 
was bound to BD Falcon Pro-Bind 96 well plates over night at 4°C. Antigen was diluted 
in 1.0 M sodium carbonate buffer (pH 9.8) and 0.1 ml of solution was bound in each 
well. After overnight incubation, the plate was washed 5 times with PBS, and blocked 
with 0.3 ml BSA-PBST for 2 to 3 h at room temperature. ELISA was performed as per 
instructions provided by the Idexx HerdChek® ELISA (Idexx Laboratories, One Idexx 
Drive, Westbrook, ME). Briefly, sera were diluted 1:25 in either BSA-PBST the buffer 
supplied by Idexx® containing M. phlei antigen for clarification. Diluted serum was 
applied (0.1 ml) to each well and incubated for 30 min at room temperature, plates were 
washed 5 times with PBS, and secondary antibody conjugate (Horse Radish Peroxidase 
(HRP) conjugated rabbit anti-bovine IgG) applied (0.1 ml/well) and incubated for 30 min 
at room temperature. After additional washing steps, 0.1 ml tetramethyl-benzadiene 
(TMB) was added and the subsequent reaction was stopped with the supplied SDS-stop 
solution, as appropriate color developed. Absorbance was read at 650 nm with a 
Molecular Devices Vmax Kinetic Microplate Reader and translated with xChek software 
from Idexx®.  Statistical analysis of ELISA results was performed using SAS 9.2 for 
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Windows (SAS institute Inc., Cary, NC).  To compare average absorbance of all 
seropositive cattle samples to the seronegative group, mixed model regression (MIXED) 
analysis was performed factoring the repeated measures for day and serum sample.  To 
evaluate within and between antigen sera combinations, the generalized linear mixed 
models regression (GLIMMIX) analysis was used.  A P value of < 0.05 was considered 
significant. 
   
Results 
 
Bioinformatic analysis of MAP1152-MAP1156 gene cluster. Nine PE and 37 PPE 
protein genes are scattered around the MAP chromosome (Fig. 1). The major PPE cluster 
is at 1.66 Mb in the clockwise direction in the published genome sequence (99) and 
comprises MAP1514, encoding a PE protein, and six PPE genes. The MAP1152-
MAP1156 region of interest for this study is the second major cluster and is located at 
1.21 Mb in the clockwise direction. This region encodes the PPE proteins MAP1152 
(40.8 kDa), MAP1153 (45.8 kDa), and MAP1155 (32.3 kDa) (Fig. 1, inset). This region 
also encodes a putative unknown function ORF (MAP1154, 11.8 kDa) and MAP1156 
(50.7 kDa), a member of the uncharacterized protein family (UPF0089; 
http://pfam.sanger.ac.uk/family/PF03007). The MAP genome encodes nine UPF0089 
family genes and MAP1156 is the only member that is immediately adjacent to a PPE 
gene (Fig. 1). This cluster does not encode a PE protein sequence.  
It is tempting to speculate that genes in the MAP1152-MAP1156 region are 
organized in a functional unit since ORFs further upstream and downstream are 
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transcribed from the complementary strand with short (e.g., < 200 bp) intergenic regions. 
However, the more stringent predictions indicate that only MAP1152 and MAP1153 are 
organized in a true operon with a pOp (estimated probability that a pair of genes is in the 
same operon) value of 0.842 (http://www.microbesonline.org/operons/gnc262316.html 
(129, 130)). Nonetheless, the genes in this cluster may comprise more than one operon. 
The proximal (MAP1152) and distal (MAP1156) ORFs in the cluster were 
selected for immunological tests of humoral immunity in infected and non-infected 
animals. MAP1152 encodes a typical PPE protein of 416 amino acids with a predicted 
molecular mass of 40.8 kDa (Table 2).  Protein structure analysis predicts for the best 
model three trans-membrane helices (http://www.predictprotein.org) (139) consistent 
with a surface/membrane localization as shown for other PPE proteins (19, 69, 106, 112, 
127).  MAP1156 is a protein of 464 amino acids with a predicted molecular mass of 50.7 
kDa.  Protein structural analysis for the best fit model predicts one trans-membrane helix 
suggesting surface localization (139).  Both MAP1152 and MAP1156 have homologous 
sequences in both MAP and other mycobacterial genomes. Further bioinformatic analysis 
of the ORFs in the cluster is presented in Table 2. 
Seroreactivity of recombinant proteins by immunoblot analysis. Purified 
recombinant proteins MAP1152 and MAP1156 were subjected to SDS-PAGE and 
immunoblot analyses. Equal amounts of both proteins were examined by SDS-PAGE to 
verify that their migration corresponded with molecular size (Fig. 2, SDS-PAGE Panel). 
Both fusion proteins migrated to the expected positions between the 75-kDa and 100-kDa 
protein markers, with MAP1156 (90.6 kDa) located slightly higher than MAP1152 (82.8 
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kDa). Likewise, LacZ (42 kDa) migrated to a position below the 50-kDa marker. These 
data indicate that MBP method resulted in protein preparations of the necessary purity 
and yield to carry out further testing. MAP1156 did show multiple bands in contrast to 
the discrete single bands observed for MAP1152 and LacZ. Immunoblot quality control 
analysis was also performed using a monoclonal antibody developed to the MBP affinity 
tag. All three MBP fusion proteins were detected by this antibody (Fig. 2, MBP mAb 
Panel). The additional bands observed in the MAP1156 preparation likely represent 
degradation products with the same N-terminus, as the fast-migrating bands reacted also 
with the MBP monoclonal antibody. 
The immunogenicity of the recombinant proteins was tested by immunoblotting 
using immune mouse (C57BL/6 Black) or rabbit (New Zealand White) serum from 
animals immunized with a live preparation of MAP, as described previously (11).  The 
mouse serum displayed little to no reactivity to MAP1152, but strong reactivity to 
MAP1156 with the most intense band migrating between the 50 and 75 kDa markers 
(Fig. 2, Mouse 160 Panel).  The rabbit immune serum showed strong reactivity to both 
proteins (Fig. 2, Rabbit 273 Panel).  Reactivity against the LacZ antigen carrying the 
MBP-tag was used as a negative control.  The mouse serum displayed no MBP-LacZ 
reactivity (Fig. 2, Mouse Panel, lane 4) and only a weak reaction was observed with the 
rabbit serum (Fig. 2, Rabbit Panel, lane 4).  Thus, the MBP tag yielded no to minimal 
reactivity in these immunoblots. 
Immunoblots were also performed with sera from five cattle naturally infected 
with MAP (Fig. 3A, Panels 183, 2075, 184, 805, and 45). MAP1156 (Fig. 3A, lane 3, all 
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Panels) showed higher levels of reactivity compared to MAP1152 (Fig. 3A, lane 2, all 
Panels). Furthermore, densitometry analysis (Table S1, Supplemental Material) enabled a 
semi-quantitative comparison and showed that MAP1156 displayed 2- to 5-fold more 
seroreactivity than MAP1152 among these MAP seropositive samples. Conversely, weak 
reactivity was observed with sera from cattle experimentally infected with M. avium or 
M. bovis (Fig. 3B). 
We also followed the reactivity of the proteins against serum samples taken at 
different time points during natural infection.  Samples corresponded to bleeds taken 9-14 
months apart, corresponding to disease progression from subclinical to clinical disease.  
Results obtained with these samples (Fig. 4) indicated that MAP 1152 did not react with 
any of the serum samples (Fig. 4, Upper Panel, lanes 1-4), while MAP1156 (Fig. 4, 
Middle Panel, lanes 1-4) and MAP K-10 whole cell extract (Fig. 4, Lower Panel) 
displayed increasing reactivity with samples from subclinical (Fig. 4, lanes 1 and 2) to 
clinical stages (Fig. 4, lanes 3 and 4).  Both proteins reacted with the anti-MBP 
monoclonal antibody control (Fig. 4, lane 5), albeit MAP1152 yielded a weaker reaction.   
Seroreactivity of recombinant protein with sera from MAP-infected and non-
infected cattle by ELISA. As the ELISA technology is readily adaptable to diagnostic 
applications, we also determined the reactivity of MAP1152 and MAP1156 by this 
method. In addition, this assay is generally performed allowing the antigen-antibody 
reaction to take place in the absence of denaturing agents. Thus, both linear and 
conformational epitopes may contribute to the overall reactivity. Due to limiting amounts 
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of serum samples, the ELISA was performed using archived serum samples, previously 
evaluated by the Idexx® test in the Veterinary Diagnostic Laboratory (Table 1).  
Each sample was tested in triplicate against LacZ (negative control antigen), and 
on three different days in duplicate (day 3) or triplicate (days 1 and 2), to evaluate 
reproducibility and performance, against MAP1152, MAP1156, and a standard MAP 
antigen control (Idexx® antigen, a proprietary mixture of MAP antigens) included in the 
Idexx® test kit (Supplemental Material, Table S2).  Each antigen showed low reactivity 
and a small variability as tested against seronegative serum samples from non-infected 
cattle.  As expected, the differences in absorbance means of samples from MAP infected 
versus non-infected cattle were statistically significant for antigens MAP1152 (P ≤0.01), 
MAP1156 (P ≤ 0.05) and Idexx® (P ≤ 0.001) with more variable results for MAP1156 
and the Idexx® antigens (Table S3, Supplemental Material).  In contrast, the difference in 
absorbance means was not significant for the LacZ negative control (P > 0.05). However, 
the reactivity of seropositive samples against LacZ was also more variable as indicated 
by the error bars (Fig. 5). MAP capture antigens were able to differentiate, in the 
combined analysis, between the groups of seropositive and seronegative samples.  Thus, 
MAP infection results in a humoral response directed against epitopes present in 
MAP1152, MAP1156, and the Idexx® antigen. However, absorbance values using 
MAP1152 and MAP1156 as the capture antigens were lower than those attained with the 
Idexx® capture antigen. This performance is not surprising because these results were 
obtained with the standardized Idexx® test protocol.  
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Comparative analysis of the reactivity of each serum-antigen combination was 
also carried out (Fig. 6). Reactivity trends were similar for both MAP1152 and MAP1156 
as all samples with higher absorbance readings for MAP1152 also yielded higher values 
for MAP1156. The Idexx® antigen followed a similar trend, except for the positive 
control as all three MAP antigens yielded similar absorbance. In contrast, three 
seropositive samples (EDNA, 308 and 2010-07) yielded significantly higher absorbance 
for the Idexx® antigen than for MAP1152 and MAP1156. No samples were expected to 
yield above background absorbance readings with LacZ, the negative antigen control 
carrying the MBP tag. However, the EDNA serum sample displayed approximately 4 
times higher absorbance readings than any other sample. 
Both statistical analysis using GLIMMIX and calculation of sample to positive 
(S/P) ratios for the Idexx® antigen yielded the same classification as the original test 
(Tables S2 and S4, Supplemental Material).  As cutoff values for S/P ratios are dependent 
on the particular assay procedure, capture antigen, and selection of an appropriate 
positive control serum, GLIMMIX provides the more accurate analysis for the 
recombinant antigens.  Absorbance means for each antigen–serum combination were 
compared to each other and samples were classified as positive or negative based on the 
P value obtained for the comparison against the negative control serum for the test 
antigen.  This analysis indicated that the non-specific MBP-LacZ antigen control 
identified all samples, except EDNA, as seronegative; in contrast, antigens MAP1152 and 
MAP1156 misclassified only the seropositive sample 2010-07 as seronegative (Table S4, 
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Supplemental Material).  Thus overall, all MAP antigens yielded a classification of serum 
samples consistent with the original test. 
 
 
Discussion 
Development of effective strategies for the control of JD remains as one of the 
most challenging issues in animal health (33, 46). Advances in MAP genomics and 
molecular genetics provide an integrated rational approach to solve this problem (9, 12, 
99).  In this context, the search for new diagnostic tests is most effective if combined with 
novel approaches to vaccination and knowledge of what the test indicates regarding the 
underlying mechanisms of disease pathogenesis. Targeting the MAP1152-MAP1156 
gene cluster was based on the identification of an attenuating mutation possibly related to 
the expression of this cluster, and a potential role of the encoded proteins as B- or T-cell 
antigens. An attenuated mutant may serve as a candidate live-attenuated vaccine strain 
and the protein as a subunit vaccine or diagnostic indicator; all relevant aspects are 
combined into an integrated approach. 
In this study, we demonstrate that both MAP1152 and MAP1156 encode reactive 
B-cell epitopes, a result predicted from the surface localization implied by in-silico 
analysis (Table 2). This finding is also consistent with prior experimental evidence on 
other PE/PPE proteins. For example, the MTB protein Rv2430c (PE25) was identified as 
a strong B-cell antigen (26) and the seroreactivity of MAP Rv1818c was demonstrated in 
cattle (113). In contrast, antigens MAP1518 (Map41, ortholog of Rv1808 [PPE32]) and 
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MAP3184 (Map39, ortholog of Rv3135 [PPE50]), the M. avium strain 104 MaPE protein, 
and the cell-wall associated MTB protein Rv3873 (PPE68) serve as T-cell antigens (112, 
118, 122).  
MAP1152 and related PPE proteins MAP1153, and MAP1155 are members of the 
ancestral PPE sublineage IV (63). The genes encoding these proteins belong to an 
ancestral cluster that underwent duplication events from ancestral ESAT-6 clusters but 
without a concomitant duplication of the ESAT-6 genes and thus, these paralogs are no 
longer associated with the ESAT-6 genes. PE/PPE genes are usually organized in operons 
encompassing at least several PE and/or PPE members (136, 166). Biochemical evidence 
indicates that PE and PPE function in pair-wise combinations of interacting proteins 
exposed to the cell surface (42, 136, 161) with the larger size PPE proteins providing a 
pocket for the PE partner (161). However, MAP1152 is organized in a cluster devoid of 
coding sequences for PE proteins. Because the probability of PPE proteins participating 
in pair-wise associations decreases for unlinked PE and PPE genes (136), the function of 
MAP1152 may or may not require a PE partner. Instead, MAP1152 may play additional 
roles in the mechanisms of pathogenesis, as shown for other PE/PPE proteins. For 
example, MTB transposon mutants of the PE/PPE genes Rv1807 (PPE31), 
Rv3872(PPE35), and Rv3873 (PPE68) are attenuated in mice (145). Likewise, a 
transposon mutant in the M. avium PPE gene homologous to Rv1787 (PPE25) displayed 
impaired growth in macrophages, reduced virulence in mice, and failed to prevent 
phagosome acidification (82, 100). Thus, a group of PE and PPE proteins may be 
necessary for intracellular survival. 
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MAP1156 is also a B-cell antigen, stronger than MAP1152 in Western blot 
reactivity, a property also consistent with its inferred surface localization. MAP1156 
belongs to the uncharacterized protein family UPF0089. MTB encodes 15 members of 
this family that include proteins with triacylglycerol synthase (TGS) activity (38). The M. 
tuberculosis ORF Rv1425 is the closest homologue to MAP1156 (Table 2), but this ORF 
has been shown not to possess significant TGS activity, at least under the conditions 
tested. One possible role consistent with a strong humoral reaction is that this ORF was 
hitchhiked by MAP into a co-expression unit that modulates the immune response. 
Microorganisms of the MTB complex possess a large number of PE-PGRS proteins that 
are associated with immunoregulatory roles (13, 41). However, as indicated above, the 
MAP evolutionary lineage separated prior to the further expansion of the ESAT-6 Region 
V that gave rise to the PE-PGRS and PPE-MPTR sublineage V PE/PPE proteins (63). 
Thus, the absence of PE-PGRS proteins may require the recruitment of other proteins, for 
example MAP1156, to play this immuno-modulatory role.  Future experiments will be 
directed to identify T-cell epitopes in both MAP1152 and MAP1156.  These tests are 
indispensable to determine the major role of these antigens in immunopathogenesis.  For 
example, it is possible that the PPE protein MAP1152, the weaker B-cell antigen in 
Western immunoblotting analyses, may elicit a predominant T-cell response early in 
infection, with MAP1156 exerting a counter-modulating B-cell response, most favorable 
for MAP to maintain a chronic infection.  This hypothesis is consistent with the 
increasing MAP1156 seroreactivity observed with serum samples withdrawn as JD 
progressed from subclinical to clinical stage (Fig. 4).  However, a more detailed study of 
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linear and conformational epitopes in these proteins, especially for MAP1152, should be 
undertaken, as conformational epitopes may not be reactive in Western immunoblots.  
The B-cell reactivity of both MAP1152 and MAP1156 in Western blots and 
ELISA with serum samples from MAP-infected animals is likely associated with private 
rather than crossreactive or shared epitopes from related MAP proteins. In this context, 
the closest paralog to MAP1152 is MAP1518 with 47% identity. Likewise, the closest 
paralog to MAP1156 is MAP1969c with 38% identity (Table S5, Supplemental 
Material). The low degree of reactivity of MAP1152 in the immunoblots against sera 
from M. bovis-infected animals may be explained in a similar manner as the closest 
homologue (Mb1837) shares only 50% identity. In contrast, the low reactivity of 
MAP1156 against the M. bovis serum, and MAP1152 and MAP1156 against M. avium 
hominissuis serum, may be associated with low expression levels in these 
microorganisms. Otherwise, the corresponding proteins are highly homologous with 86 to 
99% identity (Table S5, Supplemental Material) and thus, likely to be highly 
crossreactive as most epitopes are shared. Moreover, the MAP1152-MAP11156 cluster 
organization is conserved between MAP and M. avium 104 (a sequenced isolate of M. 
avium subsp hominissuis), both genomes possessing highly homologous genes within this 
region. However, sequence divergence with M. avium 104 occurs upstream from 
MAP1152 that could affect gene regulation.  Nonetheless, to substantiate these findings 
for the development of diagnostic tests, it would be necessary to test a larger group of 
cattle infected with M. bovis, M. avium subspecies, and other environmental species such 
as Mycobacterium kansasii. 
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Interestingly, MAP1152, MAP1156 and the Idexx® antigen yielded similar 
absorbance values against the standardized Idexx® positive control bovine serum 
included in the Idexx® kit that was from a single naturally infected Holstein cow (Table 
1).  However, the other three seropositive clinical samples reacted significantly stronger 
with the Idexx® antigen (Fig. 6). As indicated above, these results may be due to 
methodological aspects, as the overall assay optimization was based on the Idexx® 
protocol.  Alternatively, or by compounding effects, the increased reactivity in these 
samples against the Idexx® antigen may in part reflect the presence of crossreactive 
antibodies against the various MAP proteins present in the Idexx® antigen. 
In summary, MAP infected cattle mount a humoral response to both MAP1152 
and MAP1156. Further research is needed to determine the value of these recombinant 
proteins as diagnostic capture antigens, subunit vaccines, markers of disease progression, 
or their suitability for the development of DIVA (diagnosis of infected from vaccinated 
animal) tests coupled with the development of live attenuated deletion mutant marker 
vaccines (27, 170). 
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Table 1.  Cattle serum samples used in the study. 
Serum  
Sample 
Original 
classification 
(Idexx test) 
Type  
of  
infection 
Source 
Cow # 183 + Natural NADC
1
 
Cow # 2075 + Natural NADC
1
 
Cow # 184 + Natural NADC
1
 
Cow # 805 + Natural NADC
1
 
Cow # 45 + Natural NADC
1
 
Cow # 193 - Experimental 
with M. avium 
hominissius  
NADC
1
 
Cow # 2291 - Experimental 
with M. bovis strain 
95-1315  
NADC
1
 
Positive 
Control
2
 
+ Experimental 
with MAP 
Idexx Laboratories 
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1
NADC, National Animal Disease Center, Ames, Ia. 
2
Positive control serum provided with the Idexx kit. 
3
Veterinary Diagnostic Center, Lincoln, NE 
4
Negative control serum provided with the Idexx kit. 
  
EDNA + Natural  NADC
1
 
Cow #308 + Natural  NADC
1
 
2010-07 + Natural Nebraska Dairy
3
 
Negative  
Control
4
 
- None Idexx Laboratories 
J53-90 - None Nebraska Beef Herd
3
 
Cow #559 - None NADC
1
 
3438-08 - None Nebraska Dairy
3
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Table 2.  Characterization of MAP1152-MAP1156 ORFs 
MAP 
ORF 
Size 
1
 MTB H37RV 
homologue/ 
E-value 
1
 
Domains and 
Motifs 
1,2
 
Comments 
MAP1152 416, 40.7 
Rv1808 (PPE32)
3
/ 
8.0 e
-78
 
PPE, 
GxxSVPxxW 
Three membrane helices 
(MH)
4
 
MAP1153 454, 45.7 
Rv1809 (PPE33)
3
/ 
1.0 e
-84
 
PPE, 
GxxSVPxxW 
 
Coding sequence starts 7 
bp downstream from 
MAP 1152.  Three MH
4
. 
MAP1154 117, 11.7 
Rv1810/ 
8.0 e
-19
 
DUF732 
super family 
Hypothetical protein. No 
MH
4
 
MAP1155 320, 32.2 
Rv1807(PPE31)/ 
4.0 e
-24
 
PPE, 
GxxSVPxxW 
Attenuating mutation in 
M. tuberculosis 
homologue (49). Two 
MH
4
 
MAP1156 464, 50.6 
Rv1425/ 
0.0 
UPF0089 
M. tuberculosis 
homologue encodes 
enzyme with low TGS 
activity (16).  Possibly 
one MH
4
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1
 Data entries based on the National Center for Biotechnology Information (NCBI) 
output.  Size given in no. of amino acids, mol wt (kDa).  E-values (blastp suite) are 
formatted as described in the Blast help manual 
(http://www.ncbi.nlm.nih.gov/blast/blast_help.shtml).   
2
 Data entries based on the Pfam database (http://pfam.sanger.ac.uk/family). 
3
 Most homologous M. tuberculosis are not necessarily orthologs (22). 
4
 Based on the PredictProtein server (http://www.predictprotein.org) for protein analysis 
(PHDhtm output). 
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Figure 1.  Genomic map of PE, PPE, and UPF encoding genes in MAP K-10.  
Genes encoding for PE (inside bars), PPE (crossing bars), and UPF (outside bars) protein 
family members are shown.  No PGRS protein encoding sequences were found.  Inset: 
MAP1152-MAP1156 genomic region indicating genes encoding PPE proteins MAP1152, 
MAP1153 and MAP1155 (black boxes), UPF protein MAP1156 (grey box), hypothetical 
protein MAP1154 (dark patterned box), and MAP1150c and MAP1151c (light patterned 
boxes).  Arrowed boxes were used to indicate the direction of transcription. 
 
 
 
 
FIGURE 1 
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Figure 2.  SDS-PAGE and immunoblot analysis of recombinant M. avium subsp 
paratuberculosis MAP1152 and MAP1156 proteins.  Shown is a 12% SDS-PAGE gel, 
stained with GelCode Blue, along with three corresponding immunoblots containing 
purified recombinant fusion proteins.  Antibody or serum samples used to probe the 
immunoblot are indicated beneath: MBP mAb, monoclonal antibody against the maltose 
binding protein; Mouse 160, serum derived from a mouse experimentally infected with 
MAP K-10; Rabbit 273, serum derived from a rabbit experimentally infected with MAP 
K-10.  Size standards, reported in kDa, are indicated to the left. Assignments for the gel 
and blots were: lane 1, protein size standards; lane 2, MAP1152; lane 3, MAP1156; and 
lane 4, LacZ. 
 
 
 
 
 
 
FIGURE 2 
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Figure 3.  Western blot analysis of antibody responses to MAP1152 and 
MAP1156 in naturally infected cattle.  Immunoblots containing MAP1152 and 
MAP1156 were probed with sera from (A) five cows (183, 2075, 84, 805 and 45) 
naturally infected with Johne’s disease, and (B) two additional cows experimentally 
infected with M. avium or M. bovis.  Size standards, reported in kDa, are indicated to the 
left.  Assignments for the blots were: lane 1, protein size standards; lane 2, MAP1152; 
lane 3, MAP1156; and lane 4, LacZ. 
 
 
 
 
FIGURE 3 
  
44 
 
 
Figure 4.  Western blot analysis of antibody responses to MAP1152 and 
MAP1156 during the course of JD.  Immunoblots of MAP1152 (upper panel), 
MAP1156 (middle panel), and K-10 whole cell extract (lower panel) were probed with 
serum samples withdrawn from a naturally infected cow (cow#47) at various times 
during the course of infection: first bleed (time zero), subclinical infection (lane 1);  12 
months, borderline clinical/subclinical infection  (lane 2);  26 month, clinical infection 
(lane 3); 35 months,  clinical infection (lane 4); and anti-MBP monoclonal antibody 
control (lane 5).  Size standards (kDa) are indicated to the left. 
 
 
 
Figure 4  
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Figure 5.  Seroreactivity of MAP1152 and MAP1156 recombinant proteins to 
infected and non-infected cattle.  Antigen (0.010 mg) reactivity was evaluated by 
ELISA against sera from cattle naturally and experimentally infected with MAP and sera 
from culture-negative cattle.  Each serum was diluted 1:25 in Idexx dilution buffer.  Each 
column represents absorbance means (triplicate wells per plate and sample assayed on 
three different days for four serum samples) per antigen ± standard errors of the mean 
from non-infected (left column for each antigen) or infected cattle (right column), as 
evidenced from the original classification of the corresponding animals.  Significance 
levels are indicated: 
*, P ≤ 0.05, **, P ≤ 0.01, and *** P ≤ 0.001. 
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Figure 6:  Individual response of serum samples from infected and non-infected 
cattle to recombinant antigens.  Antigen (0.010 mg) reactivity was evaluated by ELISA 
against sera from cattle naturally and experimentally infected with MAP and sera from 
culture-negative cattle.  Each serum was diluted 1:25 in Idexx dilution buffer.  Each 
column represents absorbance means (triplicate wells per plate and sample assayed on 
three different days for each serum sample) per antigen ± standard errors of the mean 
from non-infected (-) or infected (+) cattle, as evidenced from the original classification 
of serum samples.  Reaction to each antigen is indicated by open (LacZ), black 
(MAP1152), grey (MAP1156) and striped (Idexx antigen) columns. 
 
FIGURE 6 
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SUPPLEMENTAL TABLES OF STATISTICAL ANALYSIS 
Table S1. Density data Western blots 
Label/Sample  
Gray Value 
(Mean)  
Gray Value 
(Median)  
Integrated 
Density  
Mean 
Intensity  
MAP1152-ascites  140.010256 148  57724  4.989744  
MAP1156-ascites  57.051282 44  22250  87.948718  
MBP/LacZ-ascites  144.561538 144  56379  0.438462  
MAP1152-rabbit  88.089744 82  34355  56.910256  
MAP1156-rabbit  67.064103 52  26155  77.935897  
MBP/LacZ-rabbit  134.953846 137  52632  10.046154  
MAP1152-mAb  115.85641 114  45184  29.14359  
MAP1156-mAb  119.8 118  46722  25.2  
MBP/LacZ-mAb  134.787179 138  52567  10.212821  
MAP1152-cow 183  145.889706 146  19841  18.110294  
MAP1156-cow 183  124.080882 129  16875  39.919118  
MBP/LacZ-cow 183  153.330882 153  20853  10.669118  
MAP1152-cow 2075  145.25 146  19754  18.75  
MAP1156-cow 2075  129.235294 134  17576  34.764706  
MBP/LacZ-cow 2075  151.014706 151  20538  12.985294  
MAP1152-cow 184  138.654412 137  18857  25.345588  
MAP1156-cow 184  129.551471 130  17619  34.448529  
MBP/LacZ-cow 184  163.727941 164  22267  0.272059  
MAP1152-cow 805  148.257353 148  20163  15.742647  
MAP1156-cow 805  99.573529 101  13542  64.426471  
MBP/LacZ-cow 805  142 142  19312  22  
MAP1152-cow 45  155.301471 119  16497  8.698529  
MAP1156-cow 45  121.301471 155  21121  42.698529  
MBP/LacZ-cow 45  159.338235 152  20582  4.661765  
MAP1152-cow 193  155.419118 156  21137  8.580882  
MAP1156-cow 193  155.926471 156  21206  8.073529  
MBP/LacZ-cow 193  144.191176 144  19610  19.808824  
MAP1152-cow 2291  142.698529 143  19407  21.301471  
MAP1156-cow 2291  154.316176 154  20987  9.683824  
MBP/LacZ-cow 2291  153.275 154  24524  10.725  
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Table S2. ELISA absorbance data with descriptive statistics 
         
LacZ Antigen        
         
 Serum Samples/Absorbance @ 650 nm 
 Control 
+ 
EDNA 308 
2010-
07 
Control 
- 
J53-90 559 
3438-
08 
         
Day 1 
0.085 0.207 0.055 0.058 0.049 0.04 0.047 0.047 
0.07 . 0.061 0.057 0.045 0.043 0.044 0.04 
0.069 0.222 0.053 0.055 0.042 0.043 0.043 0.039 
         
Avg: 0.075 0.215 0.056 0.057 0.045 0.042 0.045 0.042 
S.D.: 0.0090 0.0106 0.0042 0.0015 0.0035 0.0017 0.0021 0.0044 
S.E.M.: 0.0052 0.0061 0.0024 0.0009 0.0020 0.0010 0.0012 0.0025 
         
C.V.: 12.0 4.9 7.4 2.7 7.7 4.1 4.7 10.4 
         
S/P 
Ratio: 
 0.57 0.04 0.04  -0.01 0.00 -0.01 
         
 
Table S2 (Continued)       
         
MAP1152 Antigen 
         
 Serum Samples/Absorbance @ 650 nm 
 Control 
+ 
EDNA 308 
2010-
07 
Control 
- 
J53-90 559 
3438-
08 
         
Day 1 
0.285 0.426 0.184 0.163 0.044 0.067 0.065 0.049 
0.274 0.45 0.179 0.168 0.045 0.069 0.07 0.049 
0.268 0.439 0.169 0.157 0.044 . 0.072 0.052 
Day 1 
Avg: 
0.276 0.438 0.177 0.163 0.044 0.068 0.069 0.050 
S.D.: 0.0086 0.0120 0.0076 0.0055 0.0006 0.0014 0.0036 0.0017 
S.E.M.: 0.0050 0.0069 0.0044 0.0032 0.0003 0.0008 0.0021 0.0010 
         
Day 2 
0.136 0.287 0.116 0.056 0.044 0.049 0.054 0.061 
0.189 0.238 0.102 0.061 0.046 0.056 0.059 0.063 
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0.192 0.262 0.126 0.076 0.057 0.067 0.068 0.064 
Day 2 
Avg: 
0.172 0.262 0.115 0.064 0.049 0.057 0.060 0.063 
S.D.: 0.0315 0.0245 0.0121 0.0104 0.0070 0.0091 0.0071 0.0015 
S.E.M.: 0.0182 0.0141 0.0070 0.0060 0.0040 0.0052 0.0041 0.0009 
         
Day 3 
0.279 0.349 0.186 0.088 0.043 0.05 0.077 0.112 
0.291 0.335 0.161 0.082 0.043 0.049 0.077 0.108 
Day 2 
Avg: 
0.285 0.342 0.1735 0.085 0.043 0.0495 0.077 0.11 
S.D.: 0.0085 0.0099 0.0177 0.0042 0.0000 0.0007 0.0000 0.0028 
S.E.M.: 0.0060 0.0070 0.0125 0.0030 0.0000 0.0005 0.0000 0.0020 
         
Between 
Day 
Avg: 
0.244 0.348 0.155 0.104 0.045 0.058 0.069 0.074 
S.D.: 0.0625 0.0881 0.0351 0.0518 0.0032 0.0093 0.0083 0.0316 
S.E.M.: 0.0361 0.0509 0.0203 0.0299 0.0018 0.0054 0.0048 0.0183 
         
Overall 
Avg: 
0.239 0.348 0.153 0.106 0.046 0.058 0.068 0.070 
S.D.: 0.0583 0.0829 0.0333 0.0478 0.0047 0.0092 0.0082 0.0256 
S.E.M.: 0.0206 0.0293 0.0118 0.0169 0.0016 0.0033 0.0029 0.0090 
         
Between 
Day 
C.V.: 
25.6 25.3 22.6 50.0 7.1 15.5 12.1 42.6 
Overall 
C.V.: 
24.4 23.8 21.8 45.0 10.2 15.9 12.1 36.7 
         
S/P:  1.46 0.64 0.44  0.11 0.17 0.19 
 
Table S2 (Continued)       
         
MAP1156 Antigen 
         
 Serum Samples/Absorbance @ 650 nm 
 Control 
+ 
EDNA 308 
2010-
07 
Control 
- 
J53-90 559 
3438-
08 
         
Day 1 0.269 0.559 0.215 0.134 0.046 0.117 0.094 0.054 
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0.253 0.559 0.203 0.133 0.05 0.113 0.095 0.051 
0.302 0.545 0.198 0.151 0.049 0.125 0.091 0.056 
Day 1 
Avg: 
0.275 0.554 0.205 0.139 0.048 0.118 0.093 0.054 
S.D.: 0.0250 0.0081 0.0087 0.0101 0.0021 0.0061 0.0021 0.0025 
S.E.M.: 0.0144 0.0047 0.0050 0.0058 0.0012 0.0035 0.0012 0.0015 
         
Day 2 
0.098 0.274 0.095 0.056 0.046 0.051 0.059 0.054 
0.127 0.277 0.099 0.059 0.049 0.055 0.059 0.06 
0.139 0.215 0.104 0.076 0.046 0.074 0.058 0.08 
Day 2 
Avg: 
0.121 0.255 0.099 0.064 0.047 0.060 0.059 0.065 
S.D.: 0.0211 0.0350 0.0045 0.0108 0.0017 0.0123 0.0006 0.0136 
S.E.M.: 0.0122 0.0202 0.0026 0.0062 0.0010 0.0071 0.0003 0.0079 
         
Day 3 
0.262 0.457 0.161 0.102 0.044 0.099 0.095 0.102 
0.265 0.353 0.173 0.098 0.042 0.093 0.109 0.098 
Day 3 
Avg: 
0.264 0.405 0.167 0.100 0.043 0.096 0.102 0.100 
S.D.: 0.0021 0.0735 0.0085 0.0028 0.0014 0.0042 0.0099 0.0028 
S.E.M.: 0.0015 0.0520 0.0060 0.0020 0.0010 0.0030 0.0070 0.0020 
         
Between 
Day 
Avg: 
0.220 0.405 0.157 0.101 0.046 0.091 0.085 0.073 
S.D.: 0.0855 0.1495 0.0537 0.0378 0.0028 0.0294 0.0229 0.0242 
S.E.M.: 0.0494 0.0863 0.0310 0.0218 0.0016 0.0170 0.0132 0.0140 
         
Overall 
Avg: 
0.214 0.405 0.156 0.101 0.047 0.091 0.083 0.069 
S.D.: 0.0791 0.1425 0.0499 0.0359 0.0027 0.0282 0.0204 0.0210 
S.E.M.: 0.0280 0.0504 0.0176 0.0127 0.0010 0.0100 0.0072 0.0074 
         
Between 
Day 
C.V.: 
37.0 22.5 26.2 43.7 5.8 32.1 26.8 32.9 
Overall 
C.V.: 
36.9 35.2 32.0 35.5 5.9 31.0 24.8 30.2 
         
S/P:  1.89 0.73 0.47  0.26 0.21 0.14 
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Table S2 (Continued)       
         
Idexx Antigen        
         
 Serum Samples/Absorbance @ 650 nm 
 Control 
+ 
EDNA 308 
2010-
07 
Control 
- 
J53-90 559 
3438-
08 
         
Day 1 
0.369 0.717 0.884 0.339 0.043 0.039 0.042 0.048 
0.35 0.96 0.815 0.342 0.042 0.041 0.04 0.053 
0.347 1.151 0.9 . 0.044 0.041 0.041 0.043 
Day 1 Avg: 0.355 0.943 0.866 0.341 0.043 0.040 0.041 0.048 
S.D.: 0.0119 0.2175 0.0452 0.0021 0.0010 0.0012 0.0010 0.0050 
S.E.M.: 0.0069 0.1256 0.0261 0.0012 0.0006 0.0007 0.0006 0.0029 
         
Day 2 
0.149 0.663 0.396 0.452 0.041 0.038 0.038 0.036 
0.166 0.606 0.401 0.497 0.038 0.037 0.038 0.039 
. 0.592 0.393 0.447 . 0.037 0.039 0.043 
Day 2 Avg: 0.158 0.620 0.397 0.465 0.040 0.037 0.038 0.039 
S.D.: 0.0120 0.0376 0.0040 0.0275 0.0021 0.0006 0.0006 0.0035 
S.E.M.: 0.0069 0.0217 0.0023 0.0159 0.0012 0.0003 0.0003 0.0020 
         
Day 3 
0.352 0.992 0.772 0.911 0.047 0.036 0.041 0.042 
0.367 0.984 0.696 0.786 0.049 0.041 0.042 0.042 
Day 3 Avg: 0.360 0.988 0.734 0.849 0.048 0.039 0.042 0.042 
S.D.: 0.0106 0.0057 0.0537 0.0884 0.0014 0.0035 0.0007 0.0000 
S.E.M.: 0.0075 0.0040 0.0380 0.0625 0.0010 0.0025 0.0005 0.0000 
         
Between 
Day Avg: 
0.288 0.852 0.678 0.572 0.043 0.038 0.040 0.044 
S.D.: 0.1132 0.2019 0.2483 0.2997 0.0038 0.0020 0.0015 0.0047 
S.E.M.: 0.0653 0.1166 0.1434 0.1730 0.0022 0.0012 0.0009 0.0027 
         
OVERALL 
Avg: 
0.300 0.833 0.657 0.539 0.043 0.039 0.040 0.044 
S.D.: 0.0978 0.2129 0.2248 0.2221 0.0041 0.0019 0.0015 0.0047 
S.E.M.: 0.0346 0.0753 0.0795 0.0785 0.0014 0.0007 0.0005 0.0017 
         
Between 
Day C.V.: 
39.3 23.7 36.6 52.4 8.7 5.4 3.8 10.7 
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Overall 
C.V.: 
32.6 25.6 34.2 41.2 9.4 4.8 3.8 10.7 
         
S/P:  2.8 2.2 1.8  -0.02 -0.01 0.00 
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Table S3. Mixed model regression analysis of mean absorbance differences between 
sero-positive and sero-negative samples 
         
 
Antigen 
Sero-
Positive 
Average 
Sero-
Positive 
S.D. 
Sero-
Positive 
S.E.M. 
Sero-
Negative 
Average 
Sero-
Negative 
S.D. 
Sero-
Negative 
S.E.M. 
         
 MBP-LacZ 0.101 0.0765 0.0382 0.044 0.0810 0.0405  
 
IDEXXa 0.582 0.2237 0.1118 0.042 0.3388 0.1694 
 
 MAP1152 0.212 0.1064 0.0532 0.060 0.1309 0.0654  
 
MAP1156 0.219 0.1322 0.0661 0.072 0.1583 0.0791 
 
 
Table S3 (Continued) Statistical Parameters
1
 
      
 
Antigen 
LSMeans
2
 
Difference 
LSMeans
2
 
S.E.M. 
P value 
 
      
 
MBP-LacZ 0.057 0.0382 0.1564  
 
IDEXXa 0.541 0.1139 < 0.0001  
 MAP1152 0.151 0.0535 0.0069  
 
MAP1156 0.146 0.0668 0.0323  
      
1. Data generated using SAS subroutine: 
DATA DATA1; 
SET WORK.ELISA; 
PROC MIXED; 
CLASS SEROPOS ANTIGEN DAY SERA 
MODEL ABS = SEROPOS/SOLUTION; 
RANDOM DAY SERA; 
RUN; 
2. Least Squared Mean Difference between sero-positive and sero-negative samples 
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Table S4. Generalized Linear Mixed Models Regression Analysis (GLIMMIX): 
Serum-antigen pair seroreactivity 
         
 Sera*Antigen Pairs
1
 Overall 
Absorbance 
Avg. 
Overall 
S.D. 
Overall 
S.E.M. 
LS Means 
Difference
2 P value
3
  
         
 
Control-
 
LacZ
 0.045 0.0035 0.0020 . .  
 
 Idexx 0.043 0.0041 0.0014 -0.00191 0.9747  
  MAP1152 0.046 0.0047 0.0016 0.00042 0.9944  
  MAP1156 0.047 0.0027 0.0010 0.00117 0.9842  
         
 Control+ LacZ 0.075 0.0090 0.0052 0.02933 0.6797  
 
 Idexx 0.300 0.0978 0.0346 0.25467 < 0.0001  
  MAP1152 0.239 0.0583 0.0206 0.19392 0.0012  
 
 MAP1156 0.214 0.0791 0.0280 0.16904 0.0045  
         
 
EDNA LacZ 0.215 0.0106 0.0061 0.16917 0.0343  
  Idexx 0.833 0.2129 0.0753 0.78779 < 0.0001  
 
 MAP1152 0.348 0.0829 0.0293 0.30292 < 0.0001  
  MAP1156 0.405 0.1425 0.0504 0.35954 < 0.0001  
         
 
308 LacZ 0.056 0.0042 0.0024 0.01100 0.8769  
  Idexx 0.657 0.2248 0.0795 0.61179 < 0.0001  
 
 MAP1152 0.153 0.0333 0.0118 0.10754 0.0691  
  MAP1156 0.156 0.0499 0.0176 0.11067 0.0615  
         
 2010-07 LacZ 0.057 0.0015 0.0009 0.01133 0.8732  
 
 Idexx 0.539 0.2221 0.0785 0.49381 < 0.0001  
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 MAP1152 0.106 0.0478 0.0169 0.06104 0.3007  
  MAP1156 0.101 0.0359 0.0127 0.05579 0.3440  
         
 J53-90 LacZ 0.039 0.0019 0.0007 -0.00333 0.9626  
 
 Idexx 0.039 0.0021 0.0007 -0.00208 0.9719  
  MAP1152 0.058 0.0092 0.0033 0.02442 0.6776  
 
 MAP1156 0.091 0.0282 0.0100 -0.00330 0.9110  
         
 
559 LacZ 0.045 0.0021 0.0012 -0.00333 0.9626  
  Idexx 0.040 0.0015 0.0005 -0.00658 0.9111  
 
 MAP1152 0.068 0.0082 0.0029 0.01281 0.8313  
  MAP1156 0.083 0.0204 0.0072 0.04554 0.4403  
         
 
3438-08 LacZ 0.042 0.0044 0.0025 -0.00067 0.9925  
  Idexx 0.042 0.0044 0.0025 -0.00521 0.9301  
 
 MAP1152 0.070 0.0256 0.0090 0.02242 0.7041  
  MAP1156 0.069 0.0210 0.0074 0.03717 0.5281  
 
Table S4 (Continued)       
         
 Sera*Antigen Pairs
1
 Overall 
Absorbance 
Avg. 
Overall 
S.D. 
Overall 
S.E.M. 
LS Means 
Difference
2 P value
3
 
 
         
 
Control-
 
Idexx
 0.043 0.0041 0.0014 . .  
 
 LacZ 0.045 0.0035 0.0020 0.00191 0.9747 
 
 
 MAP1152 0.046 0.0047 0.0016 0.00232 0.9589 
 
  MAP1156 0.047 0.0027 0.0010 0.00307 0.9456  
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Control + Idexx 0.300 0.0978 0.0346 0.25657 < 0.0001 
 
  LacZ 0.075 0.0090 0.0052 0.03124 0.6029  
 
 MAP1152 0.239 0.0583 0.0206 0.19582 < 0.0001 
 
  MAP1156 0.214 0.0791 0.0280 0.17095 0.0002  
         
 EDNA Idexx 0.833 0.2129 0.0753 0.78970 < 0.0001  
 
 LacZ 0.215 0.0106 0.0061 0.17107 0.0150 
 
  MAP1152 0.348 0.0829 0.0293 0.30482 < 0.0001  
 
 MAP1156 0.405 0.1425 0.0504 0.36145 < 0.0001 
 
         
 
308 Idexx 0.657 0.2248 0.0795 0.61370 < 0.0001 
 
  LacZ 0.056 0.0042 0.0024 0.01291 0.8298  
  MAP1152 0.153 0.0333 0.0118 0.10945 0.0159  
 
 MAP1156 0.156 0.0499 0.0176 0.11257 0.0132 
 
         
 
2010-07 Idexx 0.539 0.2221 0.0785 0.49571 < 0.0001 
 
  LacZ 0.057 0.0015 0.0009 0.01324 0.8255  
 
 MAP1152 0.106 0.0478 0.0169 0.06295 0.1632 
 
  MAP1156 0.101 0.0359 0.0127 0.05770 0.2010  
         
 J53-90 Idexx 0.039 0.0019 0.0007 -0.00018 0.9968  
 
 LacZ 0.042 0.0017 0.0010 -0.00143 0.9810 
 
  MAP1152 0.058 0.0092 0.0033 0.02632 0.5589  
 
 MAP1156 0.091 0.0282 0.0100 0.02595 0.5646 
 
         
 559 Idexx 0.040 0.0015 0.0005 -0.00468 0.9172  
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 LacZ 0.045 0.0021 0.0012 -0.00143 0.9810 
 
  MAP1152 0.068 0.0082 0.0029 0.01471 0.7517  
 
 MAP1156 0.083 0.0204 0.0072 0.04745 0.2927 
 
         
 
3438-08 Idexx 0.044 0.0047 0.0017 -0.00330 0.9415 
 
  LacZ 0.042 0.0044 0.0025 0.00191 0.9835  
 
 MAP1152 0.070 0.0256 0.0090 0.02432 0.5892 
 
  MAP1156 0.069 0.0210 0.0074 0.03907 0.3859  
 
Table S4 (Continued)       
         
 Sera*Antigen Pairs
1
 Overall 
Absorbance 
Avg. 
Overall 
S.D. 
Overall 
S.E.M. 
LS Means 
Difference
2 P value
3
 
 
         
 
Control-
 
MAP1152
 0.046 0.0047 0.0016 . .  
 
 Idexx 0.043 0.0041 0.0014 -0.00232 0.9589 
 
  LacZ 0.045 0.0035 0.0020 -0.00042 0.9944  
  MAP1156 0.047 0.0027 0.0010 0.00075 0.9862  
         
 Control + MAP1152 0.239 0.0583 0.0206 0.19350 < 0.0001  
 
 Idexx 0.300 0.0978 0.0346 0.25425 < 0.0001 
 
  LacZ 0.075 0.0090 0.0052 0.02892 0.6235  
 
 MAP1156 0.214 0.0791 0.0280 0.16863 < 0.0001 
 
         
 
EDNA MAP1152 0.348 0.0829 0.0293 0.30250 < 0.0001 
 
  Idexx 0.833 0.2129 0.0753 0.78738 < 0.0001  
 
 LacZ 0.215 0.0106 0.0061 0.16875 0.0149 
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 MAP1156 0.405 0.1425 0.0504 0.35913 < 0.0001 
 
         
 
308 MAP1152 0.153 0.0333 0.0118 0.10713 0.0146 
 
  Idexx 0.657 0.2248 0.0795 0.61138 < 0.0001  
 
 LacZ 0.056 0.0042 0.0024 0.01058 0.8574 
 
  MAP1156 0.156 0.0499 0.0176 0.11025 0.0120  
         
 2010-07 MAP1152 0.106 0.0478 0.0169 0.06063 0.1644  
 
 Idexx 0.539 0.2221 0.0785 0.49339 < 0.0001 
 
  LacZ 0.057 0.0015 0.0009 0.01092 0.8529  
 
 MAP1156 0.101 0.0359 0.0127 0.05538 0.2040 
 
         
 J53-90 MAP1152 0.058 0.0092 0.0033 0.02400 0.5812  
 
 Idexx 0.039 0.0019 0.0007 -0.00250 0.9542 
 
  LacZ 0.042 0.0017 0.0010 -0.00375 0.9492  
 
 MAP1156 0.091 0.0282 0.0100 0.02363 0.5871 
 
         
 
559 MAP1152 0.068 0.0082 0.0029 0.01239 0.7831 
 
  Idexx 0.040 0.0015 0.0005 -0.00700 0.8721  
 
 LacZ 0.045 0.0021 0.0012 -0.00375 0.9492 
 
  MAP1156 0.083 0.0204 0.0072 0.04513 0.3002  
         
 3438-08 MAP1152 0.070 0.0256 0.0090 0.02200 0.6131  
 
 Idexx 0.042 0.0044 0.0025 -0.00563 0.8971 
 
 
 LacZ 0.042 0.0044 0.0025 -0.00108 0.9853 
 
  MAP1156 0.069 0.0210 0.0074 0.03675 0.3986  
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Table S4 (Continued)       
         
 Sera*Antigen Pairs
1
 Overall 
Absorbance 
Avg. 
Overall 
S.D. 
Overall 
S.E.M. 
LS Means 
Difference
2 P value
3
 
 
         
 
Control-
 
MAP1156
 0.047 0.0027 0.0010 . . 
 
 
 Idexx 0.043 0.0041 0.0014 -0.00307 0.9456 
 
 
 LacZ 0.045 0.0035 0.0020 -0.00117 0.9842 
 
 
 MAP1152 0.046 0.0047 0.0016 -0.00075 0.9862 
 
         
 
Control + MAP1156 0.214 0.0791 0.0280 0.16788 0.0002 
 
 
 Idexx 0.300 0.0978 0.0346 0.25350 < 0.0001 
 
 
 LacZ 0.075 0.009 0.0052 0.02817 0.6325 
 
 
 MAP1152 0.239 0.0583 0.0206 0.19275 < 0.0001 
 
         
 
EDNA MAP1156 0.405 0.1425 0.0504 0.35838 < 0.0001 
 
 
 Idexx 0.833 0.2129 0.0753 0.78663 < 0.0001 
 
 
 LacZ 0.215 0.0106 0.0061 0.16800 0.0154 
 
 
 MAP1152 0.348 0.0829 0.0293 0.30175 < 0.0001 
 
         
 
308 MAP1156 0.156 0.0499 0.0176 0.10950 0.0126 
 
 
 Idexx 0.657 0.2248 0.0795 0.61063 < 0.0001 
 
 
 LacZ 0.056 0.0042 0.0024 0.00983 0.8674 
 
 
 MAP1152 0.153 0.0333 0.0118 0.10638 0.0153 
 
         
 
2010-07 MAP1156 0.101 0.0359 0.0127 0.05463 0.2101 
 
 
 Idexx 0.539 0.2221 0.0785 0.49264 < 0.0001 
 
60 
 
 
 LacZ 0.057 0.0015 0.0009 0.01017 0.8629 
 
 
 MAP1152 0.106 0.0478 0.0169 0.05988 0.1697 
 
         
 
J53-90 MAP1156 0.091 0.0282 0.0100 0.02288 0.5991 
 
 
 Idexx 0.039 0.0019 0.0007 -0.00325 0.9404 
 
 
 LacZ 0.042 0.0017 0.0010 -0.00450 0.9391 
 
 
 MAP1152 0.058 0.0092 0.0033 0.02325 0.5931 
 
         
 
559 MAP1156 0.083 0.0204 0.0072 0.04438 0.3083 
 
 
 Idexx 0.04 0.0015 0.0005 -0.00775 0.8586 
 
 
 LacZ 0.045 0.0021 0.0012 -0.00450 0.9391 
 
 
 MAP1152 0.068 0.0082 0.0029 0.01164 0.7959 
 
         
 
3438-08 MAP1156 0.069 0.021 0.0074 0.03600 0.4083 
 
 
 Idexx 0.042 0.0044 0.0025 -0.00638 0.8835 
 
 
 LacZ 0.042 0.0044 0.0025 -0.00183 0.9752 
 
 
 MAP1152 0.07 0.0256 0.0090 0.02125 0.6252 
 
         
1. Absorbance values for each serum-antigen pair were contrasted against the upper pair 
(bold) 
Random effect of one to three repeated measures per day across 3 days: LacZ: n =3; 1 day, 
triplicate; MAP1152, MAP1156 and Idexx: n=8; 2 days, triplicate; 1 day, duplicate 
2. Significance is determined as Restricted Estimated Maximum Likelihood (REML) 
ratio of Least Squared Means (LSMeans) 
3. Data generated using SAS subroutine: 
DATA DATA1; 
SET WORK.ELISA; 
PROC GLIMMIX; 
CLASS CLASS ANTIGEN DAY SERA; 
MODEL ABS = SERA*ANTIGEN/SOLUTION; 
RANDOM DAY; 
RUN; 
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Table S5. Percent identity and similarity of MAP1152 and MAP1156 with closest M. 
avium 104, M. bovis and MAP orthologs and paralogs.  
 
MAP 
ORF 
Ortholog/ 
Paralogs 
Species 
E-
value
1
 
% 
Identity
1
 
% 
Similarity
1
 
      
MAP1152 MAP1152 MAP 0 100 100 
MAV_3356 
2
 M. avium 104 3.0 e
-173
 98 98 
Mb1837 
(PPE32) 
M. bovis 
AF2122/97 
8.0 e
-78
 50 64 
   
Rv1808 
(PPE32) 
MTB 8.0 e
-78
 50 64 
    
MAP1518 MAP 6.0 e
-46
 47 58 
      
MAP1156 MAP1156 MAP 0 100 100 
MAV_3352 M. avium 104 0 99 99 
Mb1460 
M. bovis 
AF2122/97 
0 86 91 
Rv1425 MTB 0 85 91 
MAP1969c MAP 5.0 e
-78
 38 55 
      
1. Output from NCBI Blast (http://blast.ncbi.nlm.nih.gov) 
2. True orthologous sequence. 
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David Smith 
126 VBS 
Fair St. & East Campus Loop 
Lincoln, NE 68506 
 
Dear Dr. Smith, 
 
This letter is to request permission to use all or in-part slide 43 “Probability of purchasing 
1 or more Johne’s infected individuals” of lecture “Applying population dynamics to the 
diagnosis and control of Johne’s disease”, a lecture for VBMS 996 “Population 
Approaches to Medicine”, Spring of 2006. 
 
 
Sincerely, 
 
 
 
 
Avery Paulson 
  
ii 
 
November 4
th
, 2010 
 
Raul Barletta 
233 VBS 
Fair St. & East Campus Loop 
Lincoln, NE 68506 
 
Dear Dr. Barletta, 
 
This letter is to request permission to use all or in-part manuscript CVI00297-10 
“Immuogenicity and reactivity of novel Mycobacterium avium subspecies 
paratuberculosis PPE MAP1152 and conserved MAP1156 proteins with sera from 
experimentally and naturally infected animals”. 
 
 
Sincerely, 
 
 
 
 
Avery Paulson 
  
iii 
 
November 24, 2010 
 
ASM Journals Department 
1752 N Street, N.W. 
Washington, D.C. 20036-2904 
 
Dear Diane Smith, 
 
I respectfully request permission to reproduce the final accepted copy and all 
supplements, manuscript CVI00297-10 entitled “Immunogenicity and Reactivity of 
Novel Mycobacterium avium subsp. paratubercuIosis PPE MAP1 l52 and Conserved 
MAPI156 Proteins with Sera from Experimentally and Naturally Infected Animals”, CVI 
accepted and published on-line ahead of print 17 November 2010, as Chapter 2 of my 
Master of Science Thesis.   
 
The cover page of Chapter 2 of my thesis will include the citation "Copyright @ 
American Society for Microbiology, Clinical and Vaccine Immunology, CVI Accepted, 
published online ahead of print on 17 November 2010, doi:10.1128/CVI.00297-10".  All 
authors have granted permission (attached e-mails) and my thesis will be held in 
confidentiality until ASM permission is granted.  I passed my Thesis Defense, November 
19th, 2010.  My thesis will be deposited with the Dean of Graduate Studies and the 
University of Nebraska – Lincoln Libraries, November 30th, 2010.  Graduation of 
Graduate Students for Fall 2010 at the University of Nebraska – Lincoln is December 
18th. 
 
Sincerely, 
 
 
 
 
Avery Paulson, B.S., M.S. 
Master of Science Candidate 
School of Veterinary and Biomedical Sciences 
University of Nebraska – Lincoln  
Fair and East Campus Loop 
Lincoln, NE 68583 – 0905  
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APPENDIX II 
 
Acronyms and Definitions 
 
Acronyms 
 
 MAP  Mycobacterium avium subspecies paratuberculosis 
 MTB  Mycobacterium tuberculosis 
 JD  Johne’s disease 
ELISA  Enzyme Linked Immunosorbent Assay 
 PBS  Phosphate Buffered Saline 
 BSA  Bovine Serum Albumin 
 PPE  Proline-Proline-Glutamine 
 MBP  Maltose Binding Protein 
 PCR  Polymerase Chain Reaction 
 RT-PCR Real Time Polymerase Chain Reaction 
 DNA  Deoxyribose Nucleic Acid 
 PPD  Purified Protein Derivative 
 MALT  Mucosal Associated Lymphoid Tissue 
 JDIP  Johne’s Disease Integrated Program 
 ECM   Extracellular Matrix 
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